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ABSTRACT
Introduction: Mild bleeding symptoms are commonly encountered in the general population & amongst individuals 
with platelet disorders. One of the possible causes is due to reduced number of dense granules synthesis in platelets 
and defective release of its contents. This study was aimed to evaluate platelets mepacrine-labelled dense granules 
storage and release using flow cytometry in healthy individuals and those presenting with mild bleeding symptoms.
Methods: This study was conducted at the National Blood Centre (NBC) and Faculty of Medicine and Health Scienc-
es, Universiti Putra Malaysia (UPM). Thirty- four individuals were recruited as controls (n=24) and patients (n=10). 
ADP-activated platelets and mepacrine-labelled dense granules was detected using flow cytometry. Results were 
expressed as mean fluorescent intensity (MFI) of mepacrine in resting and activated platelets; representing dense 
granules storage and release, respectively. Statistical analysis was considered significant if p ≤0.05. Results: There 
was a significant difference of mean MFI between resting (1284.3 ± 91.8) and activated platelets (1233.8 ± 107.8) 
of overall respondents with mean difference of 50.5 (p<0.01). However, there was no significant difference of mean 
MFI in resting and activated platelets between controls and patients was observed.  Conclusion: Results indicated 
there is no secretion defects in platelet dense granules among patients in comparison with controls. Flow cytometry 
provides alternative way of dense granule assessment in patients presented with mild bleeding symptoms.
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INTRODUCTION
Any defects affecting the haemostasis process can 
cause bleeding symptoms. However, mild-to-moderate 
bleeding disorders can be difficult to detect as symptoms 
like recurrent epistaxis or easy bruising are also common 
among healthy individuals (1). In a healthy population, 
the lowest values reported for bleeding symptoms were 
25% in men and 46% in women (2).
These symptoms might be clinically insignificant yet 
pose an increased risk to develop severe haemorrhage 
after surgery or trauma (1,3,4). Mild bleeding disorders 
may be caused by abnormality of vWF and platelet 
defects (1). The prevalence of von Willebrand disease 
(vWD) with clinically significant symptoms is 1 in 1000 
(5), whereas prevalence of platelet defects in the general 
population has not been established (6). 
Inherited platelet secretion disorders (PSD) include 
defective release of dense granules contents in response 
to platelet activation and reduced number of dense 
granules synthesis. Granules secretion defect may 
be caused by abnormal platelet receptors, signaling 
pathway and/or granules biogenesis. A recent review 
reported that platelet secretion defects may be more 
prevalent than von Willebrand disease (vWD) which 
has been estimated to constitute more than 90 % of 
all inherited platelet disorders (7). In contrary, in a 
worldwide survey estimated suspected inherited platelet 
function disorders of approximately 1586 patients, 
9.3% and 10.4% of families were diagnosed to have 
reduced dense granules storage (which include δ–SPD, 
Hermansky-Pudlak syndrome and Chediak-Higashi 
syndrome) and granules release defect, respectively (8), 
showing a low prevalence of the disorders globally.
Patients suspected of inherited mild bleeding disorder 
will undergo several laboratory investigations such 
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as platelet aggregation test to assess platelet function 
in response to specific agonists. Turbidimetric light 
transmission aggregometry (LTA) is considered the gold 
standard for platelet function testing (9). However, 
measurement of platelet granules specifically the 
δ-granules is also deemed important since PSD patients 
have been reported to display normal LTA responses (7). 
Flow cytometric analysis of platelet dense granules using 
mepacrine as a fluorescent marker to evaluate both 
dense granules storage and release had been described 
(10,11). Here we reported dense granules evaluation 
among the local population comparing patients 
presented with mild bleeding symptoms suspected to 
have ADP receptor defect and normal controls using 
similar methods with some modifications. 
MATERIALS AND METHODS
Ethical approval
This study was conducted at National Blood Centre 
(NBC), Kuala Lumpur and Faculty of Medicine and 
Health Sciences, Universiti Putra Malaysia (UPM), 
Serdang, Selangor. Institutional ethical approval was 
granted by UPM and Ministry of Health Medical 
Research Ethical Committee. Written informed consent 
was obtained from all respondents prior to participation 
in the study.
Study population and sampling
Patients who presented with bleeding symptoms and 
had platelet aggregation of <65% final aggregation 
in response to ADP 20 µM suggestive of familial 
inheritance and/or their family members were recruited. 
Less than 65% final aggregation is the local cut-off value 
for impaired aggregation in response to ADP agonist. 
They were identified from records of patients who were 
referred for platelet aggregation test at the NBC from 
January 2009 to May 2011. Controls were recruited from 
blood donors at NBC or healthy individuals without 
known bleeding disorders. Platelet light transmission 
aggregometry (LTA) was performed concurrently in 
all controls showing results within reference range. 
Individuals with known bleeding disorders due to 
drugs or other underlying medical/surgical problems or 
foreigners were excluded from the study. 
Mepacrine release assay was part of the tests performed 
in this selected population of suspected ADP receptor 
defects in the center. The demographic and relevant 
findings which include LTA and coagulation results of 
the population were published earlier (12 )
Blood sampling
Approximately 1.8 mL venous blood drawn into 2 mL 
3.2% sodium citrate tube (BD Vacutainer®, USA). 
Mepacrine solution preparation
Mepacrine staining solution was prepared using 
quinacrine dihydrochloride (Sigma Life Science, U.S.A) 
at 8.5 mM in Hank’s Balanced Salt Solution (HBSS) 
without Ca2+ and Mg2+. Prior to addition of HBSS, the 
powder was dissolved in dimethyl sulfoxide (DMSO), 
EMSURE® ACS (Merck, USA). For 0.08 g mepacrine 
powder, approximately 500 µL DMSO was added. The 
solution was incubated at 37oC in water bath until it 
became transparent. The pH was adjusted to pH 7.4. 
The solution was kept at 4oC and stable for up to 4 
months (11).
HEPES buffer preparation
HEPES buffer was prepared to maintain an optimal 
condition for the platelets. Components of the buffer 
include 20 mM HEPES solution, 137 mM NaCl, 2.7 mM 
KCl, 1mM MgCl2, 5.6 mM glucose and 1 g/L bovine 
serum albumin (BSA). pH was adjusted to 7.4 and kept 
at 4oC.
Sample preparation
Collected venous blood collected were processed 
within 4 hours after collection. Then 60 µL of blood 
were diluted 1:40 in HEPES buffer. Then, 123 µL of 
the diluted sample were transferred into plastic tubes; 
labeled as TA–activated platelets, TR–resting platelets. 
For identification of platelets population, 5 µL antibody 
PE-CD42b (BD Pharmingen™, USA) was added into 
both tubes and samples were gently mixed. This was 
followed by adding 20 µL ADP (BioData Corp. USA) 
to get a 10 µM final concentration to induce platelet 
activation (TA) and 20 µL HEPES buffer was added to 
TR. After 10 minutes, mepacrine was added into both 
tubes to get a 5.6 mM final concentration. ADP was 
used as platelet activator as the cohort of interest is 
those with suspected ADP defects; hence the research 
focuses on how exogenous ADP activates the receptors 
and its signaling pathway, thus influencing granules 
secretion. Samples were mixed and incubated in the 
dark at 37oC for 30 minutes. Later, the samples were 
stirred again and 50 µL samples were aliquoted into 5 
mL (12x75 mm) polystyrene round–bottom tubes (BD 
Falcon™, New Jersey, USA) and diluted 1:20 in HEPES 
buffer. The aliquoted sample was kept in the dark at 37 
oC until analysis within 24 hours. Unstained sample, 
PE-CD42b-stained only samples and sample stained 
with mepacrine-stained only samples were prepared as 
controls and diluted 1:20 in HEPES buffer. 
Flow cytometric analysis
Analysis of prepared samples was done using BD 
FACSCanto™ II Flow Cytometer (BD Biosciences, 
San Jose, USA) and BD FACSDiva™ software (BD 
Biosciences, San Jose, USA). Detection of mepacrine 
was performed with FITC emission configuration which 
was set at 530 nm. Ten thousand platelets events were 
acquired for analysis. Platelet population was identified 
and gated based on CD42b expression (CD42b vs SSC 
plot). Prior to sample analysis, the flowcytometer would 
be calibrated using BD Cytometer Setup & Tracking 
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Beads (BD Biosciences, San Jose, USA).
Interpretation
Content of dense granules is presented as percentage 
of cells positive for mepacrine and intensity of 
mepacrine fluorescence. Difference in the percentage 
of positive cells and mean fluorescent intensity (MFI) 
of mepacrine was compared between resting platelets 
and after activation with ADP in patients and controls. 
Percentage of positive cells and MFI in the resting 
platelets represented the dense granules storage; whilst 
percentage of positive cells and MFI in the activated 
platelets indicated the dense granules were secreted or 
not.
Statistical Analysis
All results were statistically analysed with IBM SPSS 
Statistics 21 where one-way ANOVA, paired T-test and 
independent T-test were performed accordingly and 
reported as mean (standard deviation, SD). P ≤0.05 was 
considered significant.
RESULTS
Content of dense granules in platelet resting state and 
after activation by ADP 10 µM were evaluated using 
flow cytometry. Figure 1 illustrates the difference of cell 
count and fluorescence intensity in cells positive for 
mepacrine.
MFI of mepacrine in resting platelet reflected platelet 
dense granule storage while reduced MFI in activated 
platelet reflected dense granule release, as illustrated in 
Figure 2. Referring to Table I, analysis of MFI in resting 
and activated platelet between genders showed no 
significant difference between both sexes. Same results 
were also obtained for analysis of MFI in resting and 
activated platelet across different races.
Table I: Mean MFI of mepacrine in resting and activated platelet by 
gender and race
Character-
istic
Resting platelet Activated platelet
Mean MFI 
(SD)
Coefficient 
of variation
Mean MFI 
(SD)
Coefficient 
of variation
Gender
   Male
   Female
1274.5 (77.5)
1300.1 (112.8)
6.1%
8.7%
1224.6 (100.2)
1248.6 (121.9)
8.2%
9.8%
Race
  Malays
  Chineses
  Indians
1286.3 (105.8)
1293.3 (79.7)
1268.5 (70.5)
8.2%
6.2%
5.6%
1229.5 (105.1)
1279.4 (138.2)
1193.4 (62)
8.5%
10.8%
5.2%
(n = 34)
Figure 1:  Cell count and fluorescence intensity in resting and activat-
ed platelets.  A -resting platelet    B-activated platelet.
Figure 2: Dense granules content in resting & activated platelets.      
A -resting platelet    B-activated platelet.
Referring to Table II, the result showed that there was 
significant difference between mean MFI in the resting 
(1284.3 ± 91.8) and activated platelets (1233.8 ± 107.8) 
of overall respondents with their mean difference was 
50.5 (p<0.01). Reduction of mepacrine MFI in activated 
platelet indicate that released of dense granules contents 
had occurred. Despite that, no significant difference in 
mean MFI in resting and activated platelet between 
control and patient group was observed (p>0.05). 
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weak agonist like ADP is able to cause granule release. 
Approximately 80% of dense granules were released 
upon activation with thrombin, a strong agonist (10). 
The present study demonstrated that a weak agonist such 
as ADP could activate platelets with subsequent release 
reaction of dense granules but the released granules 
from platelets were not as high as seen in the activation 
by thrombin with mean difference of MFI was 61.7 in 
controls and 23.4 in patients. ADP induces significant 
degranulation only if platelets are allowed to aggregate. 
Relatively little degranulation is observed in response to 
ADP as sample preparation for flow cytometric method 
was designed to prevent platelet to platelet aggregation. 
On the contrary, collagen and thrombin are able to 
induce maximal degranulation in the absence of platelet 
aggregation (14). 
This study was limited to a small number of patients 
which may contribute to the non-significant difference 
in results. It is therefore recommended to increase the 
number of patients in any future studies. Utilization of 
CD62P as platelet activation marker and incorporation 
of CD63 as marker of degranulation of activated platelet 
would be useful.
CONCLUSION
Mepacrine–stained dense granules storage and release 
assessed by flow cytometry were similar among patients 
with suspected ADP defects and healthy individuals. 
The flow cytometric mepacrine–stained dense granules 
storage and release analysis method is potentially useful 
for specific assessment of individuals suspected with 
platelet secretion defect involving dense granules. For 
improvement of methodology protocol, use of strong 
agonist such as collagen is preferable in addition to 
the use of a different fluorochrome for identification of 
platelet population based on CD42b. 
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